KR20210135990A - 급성 심방 세동의 치료를 위한 설카르딘 투여 - Google Patents

급성 심방 세동의 치료를 위한 설카르딘 투여 Download PDF

Info

Publication number
KR20210135990A
KR20210135990A KR1020217021861A KR20217021861A KR20210135990A KR 20210135990 A KR20210135990 A KR 20210135990A KR 1020217021861 A KR1020217021861 A KR 1020217021861A KR 20217021861 A KR20217021861 A KR 20217021861A KR 20210135990 A KR20210135990 A KR 20210135990A
Authority
KR
South Korea
Prior art keywords
sulfardine
pharmaceutically acceptable
acceptable salt
dose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217021861A
Other languages
English (en)
Korean (ko)
Inventor
수잔느 제이 로마노
게리 티 엘리오트
Original Assignee
후야 바이오사이언스 인터내셔널 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 후야 바이오사이언스 인터내셔널 엘엘씨 filed Critical 후야 바이오사이언스 인터내셔널 엘엘씨
Publication of KR20210135990A publication Critical patent/KR20210135990A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020217021861A 2018-12-13 2019-12-12 급성 심방 세동의 치료를 위한 설카르딘 투여 Ceased KR20210135990A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862779056P 2018-12-13 2018-12-13
US62/779,056 2018-12-13
US201962858324P 2019-06-06 2019-06-06
US62/858,324 2019-06-06
PCT/US2019/066003 WO2020123824A1 (en) 2018-12-13 2019-12-12 Sulcardine administration for treatment of acute atrial fibrillation

Publications (1)

Publication Number Publication Date
KR20210135990A true KR20210135990A (ko) 2021-11-16

Family

ID=69165588

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217021861A Ceased KR20210135990A (ko) 2018-12-13 2019-12-12 급성 심방 세동의 치료를 위한 설카르딘 투여

Country Status (11)

Country Link
US (4) US11364223B2 (https=)
EP (1) EP3893870A1 (https=)
JP (1) JP2022514537A (https=)
KR (1) KR20210135990A (https=)
CN (1) CN113453677A (https=)
AU (1) AU2019397511B2 (https=)
CA (1) CA3123078A1 (https=)
IL (1) IL283931A (https=)
MX (1) MX2021006933A (https=)
WO (1) WO2020123824A1 (https=)
ZA (1) ZA202104166B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113453677A (zh) 2018-12-13 2021-09-28 沪亚生物国际有限责任公司 用于治疗急性心房颤动的舒卡定施用
SG11202108160YA (en) 2019-01-29 2021-08-30 Huya Bioscience International Llc Sulcardine salts
IL298907A (en) * 2020-06-12 2023-02-01 Huyabio Int Llc Administering sulcardin for the treatment of acute atrial fibrillation
CN114984004B (zh) * 2022-05-25 2023-09-12 扬州中宝药业股份有限公司 硫酸舒欣啶在制备抗脓毒症药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1172908C (zh) 1999-12-10 2004-10-27 中国科学院上海药物研究所 N-取代苄基或苯基芳香磺酰胺化合物及其用途
CN1939298A (zh) 2005-09-29 2007-04-04 中国科学院上海药物研究所 硫酸舒欣啶固体和靶向制剂及其制备方法
JP5308333B2 (ja) 2006-06-30 2013-10-09 シグマ−タウ レア ディジージズ エスィアー Ｌ−アスパラギナーゼｉｉを産生する組換え宿主
EP2468869B1 (en) 2007-01-31 2015-03-18 Pfenex Inc. Bacterial leader sequences for increased expression
EP2501380B1 (en) * 2009-11-17 2016-01-27 Huya Bioscience International LLC Slow infusion of sulcardine and its salts
EP2501381B1 (en) * 2009-11-17 2017-07-26 Huya Bioscience International LLC Treatment of atrial fibrillation
KR20130072201A (ko) 2010-03-30 2013-07-01 피페넥스 인크. 재조합 독소 단백질의 고수준 발현
KR102092225B1 (ko) 2014-04-30 2020-03-23 주식회사 엘지화학 고효율 분비능을 가지는 단백질 분비 인자 및 이를 포함하는 발현 벡터
CN107532190B (zh) 2014-12-01 2021-07-09 菲尼克斯公司 用于肽生产的融合伴侣
AU2016272089B2 (en) 2015-06-03 2021-02-18 Triastek, Inc. Dosage forms and use thereof
AU2017261372B2 (en) 2016-05-05 2019-02-14 Triastek, Inc. Controlled release dosage form
EP3573602A4 (en) 2017-01-26 2020-09-16 Triastek, Inc. DOSAGE FORMS OF CONTROLLED RELEASE AT SPECIFIC GASTROINTESTINAL SITES
CN113453677A (zh) 2018-12-13 2021-09-28 沪亚生物国际有限责任公司 用于治疗急性心房颤动的舒卡定施用
SG11202108160YA (en) 2019-01-29 2021-08-30 Huya Bioscience International Llc Sulcardine salts

Also Published As

Publication number Publication date
IL283931A (en) 2021-07-29
AU2019397511A1 (en) 2021-07-22
MX2021006933A (es) 2021-09-30
US20250302805A1 (en) 2025-10-02
US20240115548A1 (en) 2024-04-11
US12357611B2 (en) 2025-07-15
WO2020123824A1 (en) 2020-06-18
AU2019397511B2 (en) 2025-08-21
CN113453677A (zh) 2021-09-28
US20200188357A1 (en) 2020-06-18
JP2022514537A (ja) 2022-02-14
CA3123078A1 (en) 2020-06-18
US11883380B2 (en) 2024-01-30
EP3893870A1 (en) 2021-10-20
US20220280480A1 (en) 2022-09-08
US11364223B2 (en) 2022-06-21
ZA202104166B (en) 2023-11-29

Similar Documents

Publication Publication Date Title
US12357611B2 (en) Sulcardine administration for treatment of acute atrial fibrillation
US4693995A (en) Pharmaceutical composition for the treatment of acute myocardial ischemia
US20110166220A1 (en) Dronedarone for the prevention of permanent atrial fibrillation
US20120309810A1 (en) Treatment of atrial fibrillation
US20110166221A1 (en) Use of dronedarone for the preparation of a medicament for use in the prevention of cardioversion
Advani et al. Pharmacodynamic, pharmacokinetic and antiarrhythmic properties of d-sotalol, the dextro-isomer of sotalol
US12465587B2 (en) Sulcardine administration for treatment of acute atrial fibrillation
JP2011517694A (ja) ドロネダロンと少なくとも１つの利尿薬の組み合わせおよびこの治療的使用
EA045624B1 (ru) Введение сулькардина для лечения острой фибрилляции предсердий
US20260041665A1 (en) J-Tp Protection
HK40061591A (en) Sulcardine administration for treatment of acute atrial fibrillation
Jaffe Use of intravenous diltiazem in patients with acute coronary artery disease
WO2023164431A1 (en) Uses of bupivacaine multivesicular liposomes as stellate ganglion block
EP2387996A1 (en) Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular events in patients with permanent atrial fibrillation
DE FERRARI et al. Perspectives from Clinical Trials
HK1155668A (en) Dronedarone for the prevention of permanent atrial fibrillation
HK1155667A (en) Dronedarone for the prevention of cardioversion

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601